Tanya Wroblewski, M.D.

Stories

FDA approves Mimrylo, first-of-its-kind drug for polycythemia vera

Announced the Mimrylo approval

Polycythemia vera has been treated with bloodletting for more than a century. On August 28, the FDA approved Mimrylo (rusfertide), the first drug that works instead by mimicking hepcidin, the hormone that limits iron available for new red blood cells.

Updated Yesterday

Notable Quotes

People living with polycythemia vera have long faced the challenge of managing a chronic blood disorder with frequent blood draws to help address the consequences of the red blood cell overproduction. Today's approval of Mimrylo offers a new, first-in-class option that has the potential to meaningfully reduce patient burden.

from FDA approves Mimrylo, first-of-its-kind drug for polycythemia vera · Updated Yesterday